Skip to main content
. 2019 Apr 29;71(6):829–838. doi: 10.1002/acr.23788

Figure 3.

Figure 3

Adjusted mean changes from baseline over time for A, SF‐36 PCS and MCS scores and B, FACIT–Fatigue scores. The timing of baseline assessments differed across the population, according to parent trial treatment. Broken lines represent the minimum clinically important difference 27, 30. Values were means‐adjusted for baseline SF‐36 MCS and PCS, FACIT–Fatigue, age, disease duration, Safety of Estrogens in Lupus Erythematosus National Assessment Systemic Lupus Erythematosus Disease Activity Index score, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index score, sex, and race. MCID = minimum clinically important difference (see Figure 1 for other definitions). * = P < 0.05; † = P < 0.01 versus placebo.